H.C. Wainwright raised the firm’s price target on Monopar Therapeutics to $6 from $2 and keeps a Buy rating on the shares. The target raise reflects the upcoming reverse split and as well as future financing option.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Announces Strategic Reverse Stock Split
- Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
- Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
- Monopar Therapeutics announces 1-for-5 reverse stock split
- Monopar Therapeutics reports Q2 EPS (10c), consensus (9c)